8:25 am Chair’s Opening Remarks

Leveraging Clinical Validation to Turbocharge Macrophage-directed Therapy Development

8:30 am Rational Combinations with Magrolimab in Hematologic Malignancies

  • Carol O’Hear Vice President, Clinical Development, Hematology Franchise Head, Gilead Sciences

Synopsis

• Demonstrating robust preclinical programs to create a rational therapeutic design and combination strategy
• Clinical efficacy of magrolimab in hematologic malignancies
• Share safety considerations of targeting CD47 and the toxicity profile seen in the clinic

9:00 am PY314: Targeting Trem2 Positive Macrophages in Patients with Advanced Solid Tumors

  • Leonard Reyno Executive Vice President & Chief Medical Officer, Pionyr Immunotherapeutics

Synopsis

• TREM2 is highly expressed on immune-suppressive TAMs within the TME, where it functions as a negative regulator of inflammatory responses
• Pionyr’s humanized IgG1 afucosylated monoclonal antibody (PY314) specifically binds human TREM2 and balances the TME (‘Myeloid Tuning’) by specifically depleting TREM2+ TAMs, via antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP)
• Preclinical and clinical results from a first in human trial of PY314 alone and in combination with pembrolizumab

9:30 am Clinical Update on Bexmarilimab – the First-in-Class Anti-CLEVER-1 mAb

Synopsis

• FiH Phase I/II study showing extended survival in last line patients
• Review biomarkers to identify responding patients
• Outline future development plans based on the FiH Phase I/II results

10:00 am
Morning Refreshment Break & Speed Networking

Preclinical & Discovery

Overcoming Challenges with Current Models to Supercharge Preclinical Results

11:00 am Integrated New Macrophage Target Discovery and Validation Engine

Synopsis

• Identifying the areas where current models do not allow for streamlined identification and validation of new macrophage targets
• Introduction to Macomics’ integrated new macrophage target discovery and validation engine.
• Future perspectives

Exploring Macrophage-directed Therapy Approaches Beyond CD47 Targeting

11:30 am Optimizing Small Molecule Approaches to Manipulate Macrophages

Synopsis

• Ensuring successful delivery of proteins to targets to accentuate mechanism of action
• Preventing off-target toxicity by targeting tumor associate macrophages

Clinical & Discovery

Incorporating an Effective Dosing Strategy to Guarantee Smooth Clinical Development

11:00 am Evorpacept: a Phase 2 CD47 Blocker Uniquely Designed for Use in Combination Therapies to Safely Maximize Anti-Cancer Activity

  • Jaume Pons President & Chief Executive Officer, ALX Oncology

Synopsis

• ALX Oncology’s lead product candidate, evorpacept, is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain
• Evorpacept has demonstrated promising clinical responses and tolerability across a range of hematologic and solid malignancies in combination with targeted antibodies, pembrolizumab, and chemotherapy
• ALX is currently enrolling subjects in multiple randomized, phase 2 studies of evorpacept in solid tumors and hematological malignancies

11:30 am Determining Safe Dosing to Prevent Off-Target Toxicity

Synopsis

• Identifying whether the response is dose-dependent to avoid excessive drug application
• Examining preclinical data and pharmacodynamic activity to determine drug dosage and frequency whilst ensuring therapeutic safety
• Utilizing a priming dose for preliminary infusion to lower the initial toxicity of therapeutic
• Assessing possible areas for toxicity to occur beyond hematologic toxicity

12:00 pm
Lunch Break & Networking

*Download the event guide to view the full event schedule.